HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Hodgkin Disease (Hodgkin's Disease)

Subscribe to New Research on Hodgkin Disease

A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.

Also Known As:

Hodgkin's Disease; Hodgkins Disease; Granuloma, Hodgkin's; Granuloma, Hodgkins; Hodgkin Lymphoma, Adult; Hodgkin's Lymphoma; Lymphocyte Depletion Hodgkin's Lymphoma; Lymphocyte-Rich Classical Hodgkin's Lymphoma; Mixed Cellularity Hodgkin's Lymphoma; Nodular Lymphocyte-Predominant Hodgkin's Lymphoma; Nodular Sclerosing Hodgkin's Lymphoma; Adult Hodgkin Lymphoma; Disease, Hodgkin; Disease, Hodgkin's; Disease, Hodgkins; Hodgkin Granuloma; Hodgkin's Granuloma; Hodgkins Granuloma; Hodgkins Lymphoma; Lymphocyte Rich Classical Hodgkin's Lymphoma; Lymphogranulomas, Malignant; Lymphoma, Hodgkin; Lymphoma, Hodgkin's; Malignant Granuloma; Malignant Granulomas; Malignant Lymphogranuloma; Malignant Lymphogranulomas; Nodular Lymphocyte Predominant Hodgkin's Lymphoma; Granuloma, Hodgkin; Granuloma, Malignant; Hodgkin Lymphoma; Lymphogranuloma, Malignant

Networked: 9264 relevant articles (718 outcomes, 1061 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Non-Hodgkin Lymphoma (Lymphosarcoma)
2.	Neoplasms (Cancer)
3.	Lymphoma (Lymphomas)
4.	Leukemia
5.	Nephrotic Syndrome (Syndrome, Nephrotic)

Experts

1.	Engert, Andreas: 83 articles (08/2015 - 01/2002)
2.	Younes, Anas: 70 articles (01/2016 - 01/2002)
3.	Diehl, Volker: 55 articles (08/2015 - 01/2002)
4.	Diehl, V: 40 articles (12/2013 - 01/2000)
5.	Borchmann, Peter: 37 articles (08/2015 - 11/2002)
6.	Engert, A: 32 articles (11/2015 - 01/2000)
7.	Bartlett, Nancy L: 31 articles (06/2015 - 02/2002)
8.	Brice, Pauline: 26 articles (12/2015 - 01/2002)
9.	Moskowitz, Craig H: 24 articles (08/2015 - 03/2004)
10.	Medeiros, L Jeffrey: 24 articles (03/2014 - 02/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Hodgkin Disease:

1.	Doxorubicin (Adriamycin)FDA LinkGeneric 01/01/1988 - "Patients with advanced Hodgkin's disease not achieving a complete remission with initial MOPP therapy are significantly less responsive to adriamycin and nitrosourea-containing regimens than patients with relapsing disease following a complete remission with MOPP. " 02/15/2002 - "Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen." 02/01/2010 - "If corroborated by further studies, therapeutic drug monitoring of doxorubicin may be warranted in patients with Hodgkin lymphoma." 02/01/2010 - "Despite many years of clinical use in Hodgkin lymphoma, no previous studies have evaluated the relationship between doxorubicin pharmacokinetics and clinical response. " 04/01/2007 - "A weekly regimen with dose escalation of doxorubicin for patients with advanced Hodgkin's lymphoma: results of a phase II study of the Groupe d'Etudes des Lymphomes de l'Adulte (GELA)."
2.	Bleomycin (Blenoxane)FDA LinkGeneric 07/01/1997 - "This study summarized results of treatment of the extraperitoneal lymphatic nodes in patients with Hodgkin's disease with infusion of oily form of bleomycin into the lymphatic vessels. " 07/01/1997 - "[A trial of applying an oily suspension of bleomycin endolymphatically in patients with Hodgkin's disease of the extraperitoneal lymph nodes]." 04/11/2015 - "With respect to our predefined non-inferiority margin, bleomycin cannot be safely omitted either, and the standard of care for patients with early-stage favourable Hodgkin's lymphoma should remain ABVD followed by IFRT. " 01/01/2015 - "Bleomycin pulmonary toxicity in adult Saudi patients with Hodgkin's lymphoma." 10/01/2014 - "Late pulmonary complications of treating Hodgkin lymphoma: bleomycin-induced toxicity."
3.	Vinblastine (Vinblastine Sulfate)FDA Link 06/01/2011 - "Here he carried out his best known clinical study-the use of vinblastine sulphate in patients with Hodgkin lymphoma. " 05/01/1979 - "randomized study of irradiation and vinblastine in clinical stages I and II of Hodgkin's disease." 06/01/1972 - "A randomized study of irradiation and vinblastine in stages I and II of Hodgkin's disease. " 04/01/2014 - "Severe neurotoxicity due to Vinblastine in Hodgkin lymphoma." 09/24/2010 - "In order to analyze the clinical relevance of the pharmacokinetic interactions between vinblastine and antiretrovirals described in literature, we evaluated all HIV-infected patients with Hodgkin's lymphoma treated with vinblastine-containing regimens and combination antiretroviral therapy, in a single clinical center. "
4.	Procarbazine (Matulane)FDA Link 01/01/1996 - "Detection of DNA methylation adducts in Hodgkin's disease patients treated with procarbazine." 04/01/1991 - "In the other, the RRM attacks may have been associated with procarbazine therapy applied for Hodgkin's disease. " 09/01/1979 - "Procarbazine [N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide hydrochloride] is used to treat Hodgkin's disease. " 02/01/1979 - "From the incidence of patients with Hodgkin's disease (1 : 42 000) the calculated population dose of procarbazine is 5.12 micrograms/kg. Assuming equal sensitivity between the sexes we can calculate, for an estimated number of 30 000 genes, the induction of about 22 mutations per million children due to procarbazine treatment. " 02/01/1979 - "Procarbazine is used in drug-combination treatment of Hodgkin's disease. "
5.	Vincristine (Oncovin)FDA LinkGeneric 09/05/2014 - "Unusual manifestations of vincristine neuropathy: report of two cases of hodgkin lymphoma." 11/01/2001 - "We report a 31-year-old women with recurrent Hodgkin's lymphoma and unrecognized HMSN-1 who developed severe motor neuropathy 3 weeks after the first cycle of treatment including 2 mg of vincristine. " 11/01/1982 - "The case history of a 24-year-old male with the nodular sclerosing form of Hodgkin's disease (stage IIE) who accidentally received an overdose of vincristine (25 mg, 0.39 mg/kg) is reported. " 04/08/1982 - "Fifteen patients with Hodgkin's disease were examined before and after each administration of vincristine sulfate (2 intravenous injections of 1.4 mg/m2 of body surface, during the first week of each month for 3 months). " 03/01/1980 - "Ten patients with Hodgkin's disease were examined before and after each administration of vincristine sulfate (2 intravenous injections of 1.4 mg/m2 of body surface during the first week of each month for 3 months). "
6.	Prednisone (Sone)FDA LinkGeneric 10/31/1962 - "[Effect of large doses of prednisone on the clinical course of advanced forms of Hodgkin's disease]." 12/01/1957 - "[Acute malignant lymphogranuloma and its treatment with prednisone]." 01/01/1975 - "[Polychemotherapy without prednisone in Hodgkin's disease]." 05/01/1992 - "Of the 21 adolescent patients with acute lymphoblastic leukemia or Hodgkin disease who were to take prednisone as outpatients, 11 patients were found to be nonadherent to treatment (52%). " 07/01/1981 - "Four patients with diffuse histiocytic lymphoma (group 1) received prednisone for 5 days every 3 weeks for five courses, and five patients with Hodgkin's disease (group 2) received prednisone for 14 days every 4 weeks for six courses. "
7.	Dacarbazine (DIC)FDA LinkGeneric 06/01/1990 - "DIC after bone marrow harvesting in a patient with Hodgkin's disease in remission." 01/01/2014 - "Impact of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and MGMT expression on dacarbazine resistance of Hodgkin's lymphoma cells." 12/01/2003 - "A psu dic(17;2)(p11.2;p21), leading to p53 deletion, was observed in a patient who developed a mixed cellularity Hodgkin's disease coexisting with the CLL/SLL in the same lymph node. " 12/22/1978 - "[DTIC--one component of ABVD combination therapy in Hodgkin's disease (author's transl)]." 07/01/2012 - "The cause of death was identified as intracerebral haemorrhage following DIC, Hodgkin's disease and recent delivery by caesarean section. "
8.	Etoposide (VP 16)FDA LinkGeneric 04/01/1999 - "ChlVPP/ABV-VP16 hybrid regimen for advanced Hodgkin's disease: a study in 36 patients." 11/15/1998 - "The effects of etoposide on testicular function in boys treated for Hodgkin's disease." 03/01/1993 - "This combination, which includes etoposide, is active for the primary treatment of advanced Hodgkin disease." 01/01/1990 - "The case of Vepesid overdosage in a patient with Hodgkin's disease." 01/01/1982 - "It is concluded that etoposide has significant activity particularly in Hodgkin's disease. "
9.	Mechlorethamine (Nitrogen Mustard)FDA Link 10/01/1970 - "Long-term remission in Hodgkin's disease after nitrogen mustard therapy." 11/01/1959 - "[Clinical studies on nitrogen mustard and roentgen therapy of Hodgkin's disease]." 05/01/1998 - "[Hodgkin's disease in two children of mother treated with nitrogranulogen]." 12/01/1992 - "Four patients with fresh Hodgkin's disease were treated with MOPP/ABV hybrid regimen using nitrogen mustard-N-oxide hydrochloride (NH2-O). " 12/01/1992 - "[Four cases of Hodgkin's disease treated with MOPP/ABV hybrid regimen using nitrogen mustard-N-oxide hydrochloride]."
10.	cAC10-vcMMAEIBA 09/01/2012 - "A phase II study of brentuximab vedotin in relapsed/refractory classical Hodgkin lymphoma (cHL) showed an impressive overall response rate of 75 % with 34 % complete responses, and median remission duration of 20 months in complete responders. " 01/01/2013 - "Although durability of the remission needs further observation, this case illustrates the excellent efficacy of brentuximab vedotin in primary refractory Hodgkin lymphoma. " 11/01/2015 - "In chemosensitive relapsed Hodgkin lymphoma, addition of brentuximab vedotin after auto-HCT improved 2-year PFS (65 vs 45%) and can be considered as an option for maintenance therapy post auto-HCT, in select higher risk patients. " 08/01/2013 - "Clinical trial results indicate that brentuximab vedotin brings considerable promise for the treatment of patients with relapsed or refractory Hodgkin's lymphoma. " 10/15/2011 - "Second, the efficacy of SGN-35, particularly in Hodgkin lymphoma, might be attributed to its effect on the tumor microenvironment. "

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 08/15/2012 - "Although most of the patients with Hodgkin's lymphoma (HL) can be cured by the current regimen of high-dose multiagent chemotherapy, the treatment causes high risks of later toxicities including secondary malignancies. " 04/01/2012 - "Most children and adolescents with newly diagnosed high-risk Hodgkin lymphoma (HL) will achieve remission and cure with conventional chemotherapy with or without radiation therapy. " 01/01/2011 - "Classical Hodgkin lymphoma is considered a highly curable disease; however, 20% of patients cannot be cured with standard first-line chemotherapy and have a dismal outcome. " 05/01/2008 - "Most patients with Hodgkin lymphoma (HL) can be cured with initial multiagent chemotherapy. " 01/01/2008 - "With the application of modern chemotherapy and radiation techniques, most patients with Hodgkin lymphoma can be cured, regardless of initial extent of disease. "
2.	Radiotherapy 07/01/2010 - "Hodgkin's disease can be cured in most cases by radiotherapy. " 05/01/2010 - "The advent of effective chemo-radiotherapy has made Hodgkin Disease (HD) a highly curable malignancy, but the great improvement in survival rates allowed the observation in long-term survivors of several treatment complications. " 01/01/2008 - "Until very recently mantle field radiotherapy remained the gold standard for the treatment of favorable early-stage Hodgkin's lymphoma. " 11/01/2006 - "Radiotherapy is very effective in local control of Hodgkin's lymphoma. " 01/01/2004 - "Our results confirm that the Stanford V regimen with consolidation radiotherapy is safe and effective in patients with bulky or advanced-stage Hodgkin's disease, achieving very high remission and overall 5-year survival rates. "
3.	Combination Drug Therapy (Combination Chemotherapy) 07/15/1995 - "Patients with Hodgkin's disease (HD) who fail to enter a complete remission after an initial course of combination chemotherapy are usually considered to have an induction failure (IF); this subset of patients has an extremely poor outcome with further conventional therapy. " 02/01/1992 - "Study population comprised 107 patients with Hodgkin's disease treated with combination chemotherapy at the National Cancer Institute who relapsed after achieving a complete remission. " 01/01/1999 - "Complete remission rates of 70-90% can be achieved following combination chemotherapy for patients with advanced-stage Hodgkin's disease (HD). " 12/01/1998 - "The patients with advanced-stage Hodgkin's disease who did not achieve a complete remission from their initial treatment with combination chemotherapy have a dismal prognosis. " 01/01/1998 - "Although 90% of adults with advanced Hodgkin's disease (HD) achieve a complete remission with new polychemotherapy regimens such as BEACOPP, it is too early to assess how many patients ultimately can be cured. "
4.	Stem Cell Transplantation 02/01/2011 - "Hodgkin's lymphoma (HL) can be cured in most of the patients, but in case of refractory disease or relapse after autologous stem cell transplantation (SCT) the prognosis becomes very poor. " 01/01/1995 - "Autologous stem cell transplantation as adjuvant treatment vs no further therapy for poor-risk Hodgkin's disease in first complete remission after MOPP/ABVD." 01/01/2012 - "Autologous stem cell transplantation (ASCT) generally provides good results in Hodgkin's lymphoma (HL). " 05/01/2006 - "We compared the safety and efficacy of allogeneic stem cell transplantation (allo-SCT) after reduced-intensity conditioning using either unrelated umbilical cord blood (UCB) donors or matched-sibling donors (MSDs) for 21 adults at high risk with advanced Hodgkin lymphoma (UCB, n = 9; MSD, n = 12). " 02/01/2003 - "Clinical and translational research initiatives that hold promise for children with Hodgkin disease in the future include: use of the WHO Classification System combining morphologic and biologic criteria; noninvasive staging procedures with increased sensitivity and specificity; development of a useful prognostic index to define groups for risk-adapted therapy; high-dose therapy with stem cell transplantation; and novel therapies."
5.	Aftercare (After-Treatment) 01/01/2011 - "Radiation-induced thyroid disorders may develop in pediatric Hodgkin's lymphoma patients in complete remission starting as early as the first year after treatment and are dose-dependent. " 08/01/1989 - "The patterns of early and late relapses (those occurring later than 3 years after diagnosis) in 432 patients achieving complete remission after treatment for stage I and II Hodgkin's disease at the Royal Marsden Hospital between 1964 and 1983 were studied to identify factors predicting for late relapse. " 01/01/1983 - "Peripheral lymphocyte chromosomes were analyzed in 55 consecutive patients with complete remission after treatment for Hodgkin's disease. " 07/24/2012 - "Long-term survival after treatment for Hodgkin's disease (1973-2002): improved survival with successive 10-year cohorts." 01/01/1993 - "Eleven months after treatment, both Wegener's disease and Hodgkin's lymphoma remained in remission."